NASDAQ:MYOK - Myokardia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $53.26 -1.93 (-3.50 %) (As of 12/17/2018 01:40 AM ET)Previous Close$53.26Today's Range$52.86 - $55.2052-Week Range$36.65 - $67.79Volume160,047 shsAverage Volume186,030 shsMarket Capitalization$2.14 billionP/E Ratio-38.04Dividend YieldN/ABeta3.44 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications; and a collaboration with 23andMe, Inc. to advance research for patients with hypertrophic cardiomyopathy. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. Receive MYOK News and Ratings via Email Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MYOK Previous Symbol CUSIPN/A Webwww.myokardia.com Phone650-741-0900 Debt Debt-to-Equity RatioN/A Current Ratio8.62 Quick Ratio8.62 Price-To-Earnings Trailing P/E Ratio-38.04 Forward P/E Ratio-29.75 P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales95.32 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book7.88 Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-45,950,000.00 Net Margins-222.07% Return on Equity-19.40% Return on Assets-16.89% Miscellaneous Employees102 Outstanding Shares40,270,000Market Cap$2.14 billion OptionableOptionable Myokardia (NASDAQ:MYOK) Frequently Asked Questions What is Myokardia's stock symbol? Myokardia trades on the NASDAQ under the ticker symbol "MYOK." How were Myokardia's earnings last quarter? Myokardia Inc (NASDAQ:MYOK) posted its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.01. The biotechnology company earned $6.64 million during the quarter, compared to analyst estimates of $6.32 million. Myokardia had a negative net margin of 222.07% and a negative return on equity of 19.40%. View Myokardia's Earnings History. When is Myokardia's next earnings date? Myokardia is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Myokardia. What price target have analysts set for MYOK? 10 brokers have issued 1-year target prices for Myokardia's stock. Their forecasts range from $70.00 to $90.00. On average, they anticipate Myokardia's share price to reach $78.00 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price. View Analyst Price Targets for Myokardia. What is the consensus analysts' recommendation for Myokardia? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia. Has Myokardia been receiving favorable news coverage? News headlines about MYOK stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myokardia earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are some of Myokardia's key competitors? Some companies that are related to Myokardia include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX) and SAGE Therapeutics (SAGE). Who are Myokardia's key executives? Myokardia's management team includes the folowing people: Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 45)Dr. June Lee, COO & Chief Devel. Officer (Age 52)Dr. Robert S. McDowell, Chief Scientific Officer (Age 60)Dr. Charles J. Homcy, Advisor (Age 70)Dr. Eric J. Topol, Advisor (Age 64) Who are Myokardia's major shareholders? Myokardia's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (7.44%), Vanguard Group Inc (7.44%), BlackRock Inc. (7.11%), Partner Fund Management L.P. (4.67%) and Foresite Capital Management IV LLC (1.27%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia. Which institutional investors are selling Myokardia stock? MYOK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Citadel Advisors LLC, Baker BROS. Advisors LP, Foresite Capital Management IV LLC, Fernwood Investment Management LLC, Morgan Stanley and Foresite Capital Management III LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr and Marc Semigran. View Insider Buying and Selling for Myokardia. Which institutional investors are buying Myokardia stock? MYOK stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Wells Fargo & Company MN, Deutsche Bank AG, Partner Fund Management L.P., Man Group plc and Teachers Advisors LLC. Company insiders that have bought Myokardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia. How do I buy shares of Myokardia? Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Myokardia's stock price today? One share of MYOK stock can currently be purchased for approximately $53.26. How big of a company is Myokardia? Myokardia has a market capitalization of $2.14 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Myokardia employs 102 workers across the globe. What is Myokardia's official website? The official website for Myokardia is http://www.myokardia.com. How can I contact Myokardia? Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected] MarketBeat Community Rating for Myokardia (NASDAQ MYOK)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 181 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 357MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: Day Trading - Risk Worth the Reward?